News : Phase III study

View:
 

Found press releases

 

Diamyd Medical's Phase III study published in the New England Journal of Medicin...

2/2/2012 2:30 AM EST  -   Diamyd Medical
An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.
The title of the published article is “GAD65...

Diamyd presents detailed results of European Phase III study

6/28/2011 10:30 AM EST  -   Diamyd Medical
Diamyd Medical AB reports detailed results from the Company’s European Phase III study of the antigen-based diabetes therapy Diamyd®, which, as previously announced, did not meet the primary efficacy endpoint.
Today, June 28, at the “American Diabetes Association’s 71st Scientific Sessions” in San Diego, California, USA, lead investigator Dr. Johnny Ludvigsson presents the detailed results of Diamyd Medical’s...

Diamyd initiates closure of US Phase III study

6/23/2011 2:30 AM EST  -   Diamyd Medical
Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd® and to initiate closure of the study.
Following consultation with the US Food and Drug Administration (FDA), Diamyd Medical has decided to suspend dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd®. Study closure activities will commence...

Diamyd closes European Phase III study

6/1/2011 2:31 AM EST  -   Diamyd Medical
Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd®.
On May 9, the Company reported that its European Phase III study with the antigen based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, although a small...

Diamyd reports initial results from European Phase III trial in patients newly d...

5/9/2011 2:30 AM EST  -   Diamyd Medical
Diamyd Medical AB reports that results from its European Phase III study with the antigen-based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.
In Diamyd Medical’s European Phase III study in recently diagnosed type 1 diabetes patients, 10 to 20 years old, the...

Last patient completes the EU Phase III study of Diamyd® antigen based therapy f...

2/14/2011 2:30 AM EST  -   Diamyd Medical
The final patient has performed the last visit of the main study period in Diamyd Medical’s European Phase III study. Treatment with the antigen based therapy Diamyd® is made to investigate whether beta cell function and thereby blood sugar control can be preserved in children and adolescents with new onset type 1 diabetes. The top line results from this study are expected to be reported as planned, in late spring...

Diamyd completes screening for US Phase III study

11/10/2010 2:30 AM EST  -   Diamyd Medical
Diamyd Medical has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.
"We expect to reach the enrollment target of 320 patients in the...

Diamyd US Phase III study well under way

3/10/2010 2:30 AM EST  -   Diamyd Medical
Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.
One hundred patients are now enrolled in the company’s US Phase III study called DiaPrevent at 33...

Diamyd’s European Phase III study fully recruited

11/12/2009 2:30 AM EST  -   Diamyd Medical
Diamyd Medical announces today that the company’s European Phase III study of the diabetes vaccine Diamyd® is now fully recruited. It is estimated that results from the study can be reported during spring 2011.
320 children and adolescents between 10 and 20 years of age and recently diagnosed with type 1 diabetes have now been identified and included in the company’s European Phase III study and have received...

Diamyd close to important milestone

10/7/2009 2:31 AM EST  -   Diamyd Medical
Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company’s European Phase III study with the diabetes vaccine Diamyd® have now been included and have received injections of Diamyd® or placebo. The company expects all participants to have been included in the study by November 2009.
Diamyd Medical is conducting a global Phase...